Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

339 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
Nogami N, Barlesi F, Socinski MA, Reck M, Thomas CA, Cappuzzo F, Mok TSK, Finley G, Aerts JG, Orlandi F, Moro-Sibilot D, Jotte RM, Stroyakovskiy D, Villaruz LC, Rodríguez-Abreu D, Wan-Teck Lim D, Merritt D, Coleman S, Lee A, Shankar G, Yu W, Bara I, Nishio M. Nogami N, et al. Among authors: socinski ma. J Thorac Oncol. 2022 Feb;17(2):309-323. doi: 10.1016/j.jtho.2021.09.014. Epub 2021 Oct 7. J Thorac Oncol. 2022. PMID: 34626838 Free article. Clinical Trial.
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer.
Stinchcombe TE, Morris DE, Lee CB, Moore DT, Hayes DN, Halle JS, Rivera MP, Rosenman JG, Socinski MA. Stinchcombe TE, et al. Among authors: socinski ma. J Thorac Oncol. 2008 Mar;3(3):250-7. doi: 10.1097/JTO.0b013e3181653cf4. J Thorac Oncol. 2008. PMID: 18317067 Free article. Clinical Trial.
Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.
Langer CJ, O'Byrne KJ, Socinski MA, Mikhailov SM, Leśniewski-Kmak K, Smakal M, Ciuleanu TE, Orlov SV, Dediu M, Heigener D, Eisenfeld AJ, Sandalic L, Oldham FB, Singer JW, Ross HJ. Langer CJ, et al. Among authors: socinski ma. J Thorac Oncol. 2008 Jun;3(6):623-30. doi: 10.1097/JTO.0b013e3181753b4b. J Thorac Oncol. 2008. PMID: 18520802 Free article. Clinical Trial.
Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer.
Stinchcombe TE, Lee CB, Moore DT, Rivera MP, Halle J, Limentani S, Rosenman JG, Socinski MA. Stinchcombe TE, et al. Among authors: socinski ma. J Thorac Oncol. 2008 Nov;3(11):1279-85. doi: 10.1097/JTO.0b013e31818b1971. J Thorac Oncol. 2008. PMID: 18978563 Free article. Clinical Trial.
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY. Kim ES, et al. Among authors: socinski ma. Lancet. 2008 Nov 22;372(9652):1809-18. doi: 10.1016/S0140-6736(08)61758-4. Lancet. 2008. PMID: 19027483 Clinical Trial.
339 results